Literature DB >> 16010686

Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies.

Karine Nguyen1, Guillaume Bassez, Rafaëlle Bernard, Martin Krahn, Véronique Labelle, Dominique Figarella-Branger, Jean Pouget, El Hadi Hammouda, Christophe Béroud, Andoni Urtizberea, Bruno Eymard, France Leturcq, Nicolas Lévy.   

Abstract

DYSF encoding dysferlin is mutated in Miyoshi myopathy and Limb-Girdle Muscular Dystrophy type 2B, the two main phenotypes recognized in dysferlinopathies. Dysferlin deficiency in muscle is the most relevant feature for the diagnosis of dysferlinopathy and prompts the search for mutations in DYSF. DYSF, located on chromosome 2p13, contains 55 coding exons and spans 150 kb of genomic DNA. We performed a genomic analysis of the DYSF coding sequence in 34 unrelated patients from various ethnic origins. All patients showed an absence or drastic decrease of dysferlin expression in muscle. A primary screening of DYSF using SSCP or dHPLC of PCR products of each of 55 exons of the gene was followed by sequencing whenever a sequence variation was detected. All together, 54 sequence variations were identified in DYSF, 50 of which predicting either a truncated protein or one amino-acid substitution and most of them (34 out of 54) being novel. In 23 patients, we identified two pathogenic mutations, while only one was identified in 11 patients. These mutations were widely spread in the coding sequence of the gene without any mutational "hotspot." (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010686     DOI: 10.1002/humu.9355

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  31 in total

1.  Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

Authors:  Bilal A Azakir; Sabrina Di Fulvio; Jochen Kinter; Michael Sinnreich
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

2.  Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.

Authors:  Soeren Turan; Alfonso P Farruggio; Waracharee Srifa; John W Day; Michele P Calos
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

3.  Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice.

Authors:  Telmo Llanga; Nadia Nagy; Laura Conatser; Catherine Dial; R Bryan Sutton; Matthew L Hirsch
Journal:  Mol Ther       Date:  2017-06-16       Impact factor: 11.454

4.  Unmasking potential intracellular roles for dysferlin through improved immunolabeling methods.

Authors:  Joseph A Roche; Lisa W Ru; Andrea M O'Neill; Wendy G Resneck; Richard M Lovering; Robert J Bloch
Journal:  J Histochem Cytochem       Date:  2011-11       Impact factor: 2.479

Review 5.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

Review 6.  Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies.

Authors:  Carolina Tesi Rocha; Eric P Hoffman
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

7.  Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.

Authors:  Bingjing Wang; Zhaohui Yang; Becky K Brisson; Huisheng Feng; Zhiqian Zhang; Ellen M Welch; Stuart W Peltz; Elisabeth R Barton; Robert H Brown; H Lee Sweeney
Journal:  J Appl Physiol (1985)       Date:  2010-06-17

Review 8.  Membrane traffic and muscle: lessons from human disease.

Authors:  James J Dowling; Elizabeth M Gibbs; Eva L Feldman
Journal:  Traffic       Date:  2008-02-04       Impact factor: 6.215

9.  Retrospective analysis and reclassification of DYSF variants in a large French series of dysferlinopathy patients.

Authors:  Théo Charnay; Véronique Blanck; Mathieu Cerino; Marc Bartoli; Florence Riccardi; Nathalie Bonello-Palot; Christophe Pécheux; Karine Nguyen; Nicolas Lévy; Svetlana Gorokhova; Martin Krahn
Journal:  Genet Med       Date:  2021-04-29       Impact factor: 8.822

10.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.